Five Centers of Nausea. Linda Tavel, MD Program Medical Director VistaCare Hospice
|
|
- Johnathan Palmer
- 6 years ago
- Views:
Transcription
1 Five Centers of Nausea Linda Tavel, MD Program Medical Director VistaCare Hospice
2 Objectives Prevalence of nausea and vomiting Anatomic and physiologic paths to nausea Evaluation of nausea Treatment of nausea Case Studies
3 Nausea Subjective sensation Often multifactorial Other symptoms occur: Sweating Salivation Tachycardia Most unpleasant of symptoms
4 It s great to be a cow. Vomiting absent in rats, rabbits, cows Rare in horses, ungulates
5 Vomiting Matter is ejected from GI tract Aka emesis (Gr.( Emein and Indo. wem ) wem Usually accompanied by nausea
6 What is vomiting? Three different actions: Salivation (from parasympathetic nervous system) Retroperistalsis,, from mid small intestine, pushing contents from digestive tract, into stomach, through relaxed pyloric sphincter Glottis closes, reducing aspiration risk Increase in abdominal pressure as muscles contract, propel stomach contents into esophagus, through relaxed lower esophageal sphincter
7 Prevalence Cancer 62% terminally ill patients--at least 40% last 6 weeks life Common in end stage heart disease Frequently seen in HIV/AIDs Liver failure Renal failure
8 Prevalence Chemotherapy Radiation therapy Opiates Medications Anorexia/cachexia syndrome
9 Causes Can be determined in most patients Up to 75% Medications Metabolic Infections Gastric slowing Constipation Always look for reversible/treatable causes first
10 Five centers. Important to determine which etiologies are involved Since multifactorial, may require more than one medication/strategy But, shotgunning not optimal Treatment aimed at underlying cause Assessment vital!
11 Assessment of Nausea and Vomiting Nausea intensity (0-10), duration, description Aggravating or activating factors QUality of life impact of N,V Symptoms accompanying N,V Emetic episodes per 24 hrs (+ timing) Alleviating factors Dahlin,, Management of Symptoms Other than Pain 2006
12 Pathophysiology of nausea / vomiting Chemoreceptor Trigger Zone (CTZ) Vomiting center Neurotransmitters Serotonin Dopamine Acetylcholine Histamine Neurokinin Cortex Vestibular apparatus GI tract
13 Where are the receptors?
14 Cortical causes of nausea Meningitis Increased intracranial pressure Anxiety (conditioning) Visual stimulus Olfactory stimulus Pain Cerebral edema due to metastases
15 Treatment of cortical pathway GABA neurotransmitter Benzodiazepines Lorazepam mg po q 4 hrs Clonazepam--longer longer acting 0.25 mg po q 12 hrs scheduled, increase q 3 days, 4 mg/d max Alprazolam--rapid rapid onset, burns off quickly mg po (panic) Treat the underlying cause!
16 Case study 41 y/o female with metastatic rectal adenocarcinoma,, multiple admissions to hospital with intractable nausea and vomiting. Resolves somewhat with hydration. Ondansetron 8 mg q 8 hrs is ineffective. Not currently receiving chemo. Patient also with fungating wound of perineum. Significant odor. Patient reports with peri- care and dressing changes the nausea worsens significantly.
17 Pathophysiology of nausea / vomiting Chemoreceptor Trigger Zone (CTZ) Vomiting center Neurotransmitters Serotonin Dopamine Acetylcholine Histamine Neurokinin Cortex Vestibular apparatus GI tract
18 Case 1 continued How would you treat her? What are the possible causes of her nausea and vomiting? Topical flagyl to wound reduced odor Lorazepam 0.5 mg po q 4 hours prn anxiety, administered prior to dressing change Dietician consult for strategies to maintain hydration
19
20 Vestibular causes of nausea Tumor at base of skull Medications Motion sickness Conflicting signals visual vs. other input
21 What are the receptors?
22 Treatment of Vestibular pathway Receptors are muscarinic and histaminergic Work through decreasing excitability of labyrinths and block conduction of vestibular-cerebellar pathway Antihistamines are sedating Anticholinergics are exciting!!! (primarily due to all those side effects) Agitation, urinary retention, constipation
23 Medications Antihistamines Diphenydramine 25-50mg 50mg po/sc/pr q 4 hr prn Hydroxyzine (Atarax)(Atarax Promethazine (Phenergan) Weak dopamine antagonist Meclizine (Antivert)(Antivert
24 Medications Anticholinergics antimuscarinics Hyoscyamine (Levsin) mg po/sl q 4 hrs prn or scheduled Atropine 1% ophthalmic drops drops sl q hrs prn Scopolamine transdermal patches 1 patch q 72 hrs Glycopyrrolate (Robinul) mg po/sc q 8 hrs
25
26 Chemoreceptor Trigger Zone Area postrema on floor of 4th ventricle Lies outside blood-brain brain barrier Medications: digoxin opiates Clonidine anticonvulsants antiretrovirals Antibiotics NSAIDs Metabolic: hypercalcemia,, uremia
27 Chemoreceptor Trigger Zone Chemotherapeutic agents Serotonin released by dying cells Immediate emetogenicity versus delayed Bacterial toxins Mechanoreceptors from increased ICP Following radiation therapy Whole body, mediastinal,, upper abdomen
28 Emetogenicity
29 Emetogenicity
30 Anatomy of CTZ
31 What are the receptors?
32 Treatment for CTZ nausea Dopamine antagonists Haloperidol 0.5 mg q hrs prn, titrate up in dose Pills, liquid, may give SQ Prochlorperazine (Compazine) ) mg po/pr q 4 hr prn Metoclopramide (Reglan)--also also 5HT4, at higher doses, 5HT3 More commonly for prokinetic action in gut 5-10 mg po/sc/pr QID, up to 100 mg/d (GI)
33 Treatment for CTZ nausea Setrons --Serotonin Setrons -- Serotonin antagonists Ondansetron (Zofran) po or IV 4-88 mg po q hrs/single IV dose (4-32mg) Granisetron (Kytril) mg po daily 4-32 mg IV once Dolasetron (Anzemet) Palonosetron (Aloxi)(Aloxi
34 Treatment for CTZ nausea Setrons --Serotonin Setrons -- Serotonin antagonists Prophylactically or routinely scheduled Very expensive!!!! Kytril or Zofran about $90 per day Others much more.
35 Treatment for CTZ nausea Substance P/NeuroKinin-1 1 receptor antagonist Aprepitant (Emend) Only for chemotherapy induced nausea 3 day regimen, po $300/3 days For delayed nausea as well T1/2 about 3 days
36 GI causes for nausea Peripheral Teeth to tail!!!!!! Biliary obstruction Constipation Gastric distension Gastroparesis Liver disease
37 GI causes for nausea Bowel obstruction Partial or complete Pharyngeal lesions Esophagitis Mucositis Visceral Pain
38 What are the receptors?
39 Treatment of GI pathway Assess fully!!! Treat the underlying condition Constipation, esophagitis,, mucositis
40 Treatment of GI pathway Prokinetic agents For gastric emptying Metoclopramide (Reglan) 5-20 mg po/pr/sq q 6 hrs Antidopaminergic at higher doses Dystonic reactions with higher doses and if combined with 5HT3 receptor antagonists, antidepressants, antipsychotics
41 Treatment of GI pathway AntiAcid agents Proton pump inhibitors Omperazole (OTC) mg/d po Lansoprazole,, mg/d Pantaprazole 40 mg/d Esmeprazole mg/d
42 Vomiting Center The final common pathway!!! Lateral medullary reticular formation in the pons Multiple receptors Histaminic, muscarinic cholinergic, 5HT2
43 What are the receptors?
44 Treatment of Vomiting Center Treat underlying cause Antihistamines Diphenydramine 25-50mg 50mg po/sc/pr q 4 hr prn Hydroxyzine (Atarax)(Atarax Promethazine (Phenergan) Weak dopamine antagonist Meclizine (Antivert)(Antivert
45 Treatment of Vomiting Center Anticholinergics antimuscarinics Hyoscyamine (Levsin) mg po/sl q 4 hrs prn or scheduled Atropine 1% ophthalmic drops drops sl q 2-44 hrs prn Scopolamine transdermal patches 1 patch q 72 hrs Glycopyrrolate (Robinul) mg po/sc q 8 hrs
46 Treatment of Vomiting Center Multireceptor antagonist: Olanzapine (Zyprexa) Antagonist D2, H1, 5HT2, Muscarinic cholinergic 5-20 mg po daily 2.5 mg SC up to 4 times daily This is off label use, but gaining favor
47 Treatment of Vomiting Center Multireceptor antagonist: Mirtazapine (Remeron) Antagonist for 5HT3, 5HT4, H1 15mg po BID Often used for anorexia off label
48 Miscellaneous treatments of nausea, vomiting Steroids Adjunctive therapy Emesis prevention in chemotherapy and radiation therapy Helpful in edema from brain metastases Also used in bowel obstruction We don t t know how steroids work..eduardo.. Bruera,MD Feb 25, 2008
49 Miscellaneous treatments of nausea, vomiting Steroids continued Dexamethasone mg po/sc 1-21 times daily Prednisone mg po daily Anti-inflammatory, inflammatory, promotes sense of well being, increases appetite
50 Miscellaneous treatments of nausea, vomiting Cannabinoid receptor antagonists Tetrahydrocannabinol (Marinol)/(Dronabinol) Indication chemotherapy related n,v HIV anorexia 2.5 mg BID po up to 20mg/day Euphoria, dysphoria 30 day supply= $284. 5HT3/metoclopramide/dexamethasone more in favor for chemotx related n,v
51 Alternative therapies Accupressure P6 best known Hypnosis Ginger Ginger ale, ginger tea, ginger candies Ginger root more effective than placebo mg ginger root qid Aromatherapy not ideal due to conditioning
52 Remember Case 1? 41 y/o with metastatic rectal cancer, Fungating rectal wound Nausea controlled fairly well with topical antibiotics and anxiolytic therapy. Continued to have low grade nausea. Why might she have nausea?
53 Where are the receptors?
54 What would you add to regimen? What tests? What interventions?
55 Pathophysiology of nausea / vomiting Chemoreceptor Trigger Zone (CTZ) Vomiting center Neurotransmitters Serotonin Dopamine Acetylcholine Histamine Neurokinin Cortex Vestibular apparatus GI tract
56 Malignant Bowel Obstruction Symptom management NG tubes occasional helpful short term Opioids for pain Anticholinergics to reduce secretions and reduce peristalsis (levsin)(levsin ( Haloperidol for nausea (concern about metoclopramide in complete obstn) Dexamethasone to reduce inflammation and?edema
57 Malignant Bowel Obstruction Octreotide Somatostatin analog Reduces gastrointestinal motility Reduces gastric, pancreatic, small intestine secretions Improves water and electrolyte absorption micrograms BID-TID SC/IV
58 Summary Five Pathways in nausea, vomiting Multiple receptors Multiple mechanisms Good assessment Treat underlying condition Add layers of medications I.e. dopaminergic,, steroid, 5HT3 Hydration
59 Case 2 UNIPAC-Selena Selena 58 y/o widow with advanced breast cancer, PPS 40%. S/P chemotherapy and radiation to chest wall, right arm, hip. Principal complaint pain in right arm and severe nausea. Meds: piroxicam (Fedlene)(Fedlene ) 20mg daily, morphine extended release 30 mg BID, theophylline slow release 300 mg BID
60 Where are the receptors?
61 Case 2 continued Nausea has been mild, chronic, increased over last 2 days when MD changed Selena from Tylenol #3 (codeine 30 mg) 1 q 4 hr prn to Morphine ER 30 mg BID. No BM for 4 days, increasing nausea at mealtime Piroxicam 20 mg for OA, now for bony mets Bronchitis,, but no hx asthma?
62 Case 2 continued What would you do? What medication changes would you make? Discontinue piroxicam Discontinue theophylline Change Morphine ER back to shorter acting opiate (oxycodone) Laxative
63 Case 2 continued Oxycodone, antacids, laxatives, and albuterol inhaler are effective Over time, escalating doses of oxycodone ER Nauseated much of the day and vomiting after eating, still with regular BMs Increased arm pain, weakness, nausea
64 Case 2 continued What medications or treatments would you offer now? Dexamethasone 4 mg Metaclopramide Haloperidol
65 Case 2 After the interventions aforementioned, Selena improves for awhile Selena experiences increasing confusion and sedation At this point, what tests or interventions?
66 Bibliography Module 3p Symptoms-Nausea/Vomiting EPEC- Oncology National Cancer Institute to order copy Storey, P. Nausea and Vomiting. UNIPAC Four: Management of Selected Non-pain Symptoms in the Terminally Ill. American Academy of Hospice and Palliative Medicine Twycross,, R Wilcock,, A. Hospice and Palliative Care Formulary USA. Palliativedrugs.com, Ltd. 2006
67 Bibliography Dahlin,, C Lynch, M et al. Management of Symptoms Other Than Pain. Anesthesiology Clin N Am 2006;(24): Montagnini,, M Moat, M. Non-Pain Symptom Management in Palliative Care. 2004;6(2): Wood, G Shega,, J Lynch, B Von Roenn,, J. Management of Intractable Nausea and Vomiting in Patients at the End of Life. JAMA. 2007;208(10): Chemotherapy-Related Nausea and Vomiting.Interactive Textbook on Clinical Symptom Research. Accessed 3/4/08
Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director
Symptom Management Nausea & Vomiting Thomas McKain, MD, ABFM, ABHPM Medical Director Mr. Jones has nausea and vomiting. May I initiate Compazine from the Comfort Pak? Objectives 1. Delineate the Differential
More informationNausea. Assessment & Management. R J Crossno, MD, CMD, FAAFP, FAAHPM. Disclosures
Nausea Assessment & Management R J Crossno, MD, CMD, FAAFP, FAAHPM Disclosures Dr. Crossno discloses his employment as Area Medical Director for VistaCare VistaCare has provided commercial support for
More informationNausea and Vomiting in Palliative Care
Nausea and Vomiting in Palliative Care Definitions Nausea - an unpleasant feeling of the need to vomit Vomiting - the expulsion of gastric contents through the mouth, caused by forceful and sustained contraction
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationApproach to Nausea & Vomi2ng
Approach to Nausea & Vomi2ng Med 3 Seminar 2017 Dr. Robin Grant Division of Pallia2ve Medicine robin.grant@nshealth.ca Why nausea and vomi2ng? Pain 80-90+ % Fa2gue / asthenia 75-90% Cons2pa2on 70% Dyspnea
More informationDECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***
Decontamination and Antiemetics Med 5724 Page 1 of 8 DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** REFERENCES: Katzung (9th ed.)
More information9/20/2017. Effectively Managing Nausea and Vomiting. Disclosure. Objectives
Effectively Managing Nausea and Myra Belgeri, Pharm.D, BCGP, BCPS, FASCP Clinical Pharmacist, Optum Hospice Pharmacy Services October 2017 1 Disclosure I have no relevant financial relationships with manufacturers
More informationA SLP s Guide to Medication Therapy and Management. Sarah Luby, PharmD, BCPS KSHA 2017
A SLP s Guide to Medication Therapy and Management Sarah Luby, PharmD, BCPS KSHA 2017 Objectives Identify the appropriate route of administration for medications and proper formulations for use Understand
More informationVomiting Approach to diagnosis
Vomiting Approach to diagnosis By Dr. Sahar El-Gharabawy Associate professor of internal medicine Hepato-gastroenterology Unit )SMH ) Mansoura University Definitions: Nausea: Feeling "sick to the stomach",
More informationUsing Evidence Based Medicine to Ethically Provide End of Life Symptom Control
Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control Erin Zimny, MD Emergency Medicine Hospice and Palliative Medicine Henry Ford Hospital Disclosures I do NOT have any financial
More informationDelirium and Nausea. Delirium - definition. Delirium Incidence. Predisposing Risk Factors for Delirium. Impact. Delirium Types 10/14/2016
Delirium - definition Delirium and Nausea Etiologically non-specific global cerebral dysfunction associated with changes in LOC, attention, thinking, perception, memory, psychomotor behavior, emotion and
More informationNausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA
Nausea & Vomiting Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Prevalence prevalence varies *, systemic review 2007 : overall prevalence : nausea 30%, vomiting 20% in last 1-2 weeks of life : nausea
More informationPart 2: Pain and Symptom Management Nausea and Vomiting
Part 2: Pain and Symptom Management Nausea and Vomiting Effective Date: February 22, 2017 Key Recommendations Select anti-nausea medication based on the etiology of the nausea and vomiting. Assessment
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationDisclosures 9/17/2018. Best Practices in the Treatment of Nausea and Vomiting
Best Practices in the Treatment of Nausea and Vomiting Jennifer Gabbard, MD Wake Forest School of Medicine jgabbard@wakehealth.edu 42 nd Annual Hospice & Palliative Care Conference September 2018 Charlotte,
More informationChapter 29 - Nausea and Vomiting
Chapter 29 - Nausea and Vomiting Episode Overview: 1) Describe the mechanism of development of a Hypochloremic Metabolic Alkalosis in vomiting 2) List commonly used anti-emetics including their dose and
More informationNausea and Vomiting. Principles and Practice in End of Life Care November 2018
Nausea and Vomiting Principles and Practice in End of Life Care November 2018 Overview Aims and Objectives Why is managing nausea and vomiting important? Definitions Causes Interventions pharmacological
More informationFirst a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.
Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,
More information3/27/2013. Objectives. Psychopharmacology at the End of Life Nicole Thurston, MD
Psychopharmacology at the End of Life Nicole Thurston, MD Psychiatrist Mountain States Tumor Institute Objectives Describe 2 common psychiatric symptoms that can present at or near end of life. Review
More informationGeneric (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 9/11/2018 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 12/16, 11/15, 11/07 LOB AFFECTED
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationManagement of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem
Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem Mary Keyes, MD KEYWORDS Postoperative nausea and vomiting PONV prophylaxis PONV in ambulatory surgery KEY POINTS
More informationSYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL
SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation
More informationGrace Ma and Andrea Weiss FMF 2018
Grace Ma and Andrea Weiss FMF 2018 Presenter: Grace Ma Relationships with financial sponsors: none Presenter: Andrea Weiss Relationships with financial sponsors: none This program has not received any
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNeuro Basics SLO Practice (online) Page 1 of 5
Neuro Basics SLO Practice (online) Page 1 of 5 1) Biogenic amines include ACh, NE, EPI and? a) Melatonin b) Dopamine c) Serotonin d) Histamine e) All of the neurotransmitters listed are biogenic amines.
More informationFirst a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.
Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,
More informationSomatostatin analogues. Other drugs
Octreotide Somatostatin analogues Lack the adverse effects of antimuscarinic agents Somatostatin decreases the release of gastrin, insulin, glucagon, gastric acid and pancreatic enzymes Also inhibits neurotransmission
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationWe would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.
We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients. The closing date for responses is 19th December The results
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationPharmacology. Drugs that Affect the Gastrointestinal System
Pharmacology Drugs that Affect the Gastrointestinal System Topics Peptic Ulcer Disease Constipation Diarrhea Emesis Digestion Peptic Ulcer Disease Factors that Increase Acidity Factors that Protect Against
More informationInpatient Palliative Medicine Update
Inpatient Palliative Medicine Update David Dupere MD, FRCPC Head, Division of Palliative Medicine Department of Medicine QEII Health Sciences Centre Halifax, Nova Scotia Disclosures Book chapter in Compendium
More informationSyringe driver in Palliative Care
Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24
More informationSecond term/
Second term/ 2015-2016 L. 1 Dr Mohammed AL-Zobaidy Learning objectives GIT pharmacology After completing this chapter the student will be able to: Recognise pathophysiological factors implicated in acid-peptic
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationPAIN. Physiology of pain relating to pain management
PAIN Physiology of pain relating to pain management What is pain? An unpleasant sensory and emotional experience associated with actual or potential tissue damage. (Melzac and Wall) The generation of pain
More informationIntroduction & Expectations Learning Objectives Etiology & Pathophysiology of Nausea & Vomiting Pharmacology of Dimenhydrinate...
Primary Care Paramedic Dimenhydrinate (Gravol) Certification Learner Package www.lhsc.on.ca/bhp 1 Table of Contents Introduction & Expectations... 4 Learning Objectives... 4 Etiology & Pathophysiology
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationLearning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016
Terminal Restlessness Dr. Christopher Churchill St. Cloud VA Health Care System EC&R Service Line Director & Medical Director Hospice & Palliative Care March 31, 2016 Learning Objectives Different Terminology
More informationManagement of Delirium in Hospice Patients
Presentation Objectives Management of Delirium in Hospice Patients Lynn Williams, BSPharm Clinical Pharmacist Hospice Pharmacy Solutions Identify the clinical features of delirium Understand the underlying
More informationScott Akin MD FAAFP
Scott Akin MD FAAFP sakin@emory.edu I have no financial disclosures Outline Review key palliative care articles of 2016 related to pain and symptom management AAHPM PC-FACS (monthly review of literature)
More informationAttach patient label here. Physician Orders ADULT: Palliative Care Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Palliative Care Phase, When to Initiate: Palliative Care Phase Admission/Transfer/Discharge Patient Status Initial
More informationAgitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety.
October 2012 4 Agitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety. Depending on appropriateness, evaluate for reversible
More informationSymptom Control in the Community Setting. Dr Andrew Tysoe-Calnon
Symptom Control in the Community Setting Dr Andrew Tysoe-Calnon Lead Consultant t Common symptoms Pain Agitation Shortness of breath Nausea and vomiting Intestinal obstruction Confusion Pain Occurs in
More informationAdvanced Symptom Management
Advanced Symptom Management Janet Bull, MD, FAAHPM Four Seasons Symptom Management o Objectives Define symptom clusters and the role of cytokines Identify different clusters and treatment options Describe
More informationDelirium and Dementia
Delirium and Dementia Elder Friendly Care in Acute Care Seniors Health Strategic Clinical Network Acute Care Stress Blender Poor Poor sleep At-Risk Older Adult TREAT CAUSE immediately & aggressively. Increased
More informationLab:2 Drugs acting on Gastrointestinal tract
Lab:2 Drugs acting on Gastrointestinal tract Drugs that used to treat three common medical conditions involving the gastrointestinal tract: peptic ulcers and gastroesophageal reflux disease (GERD), chemotherapy-induced
More informationSymptom Management Challenges at End-of-Life
Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify
More informationPalliative Medicine Overview. Francine Arneson, MD Palliative Medicine
Palliative Medicine Overview Francine Arneson, MD Palliative Medicine Palliative Medicine: Definition Palliative care: An approach that improves the quality of life of patients and their families facing
More informationWorshipping at the Porcelain Altar: Nausea and Vomiting
Worshipping at the Porcelain Altar: Nausea and Vomiting EDUARDO GODOY, MD FAMILY MEDICINE, SOUTH BAY MEDICAL CENTER TORRANCE MOB Financial Disclosures: I have no financial ties other than those owed: to
More informationCYCLIC VOMITING SYNDROME. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis
CYCLIC VOMITING SYNDROME C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis Case 26 year old male Symptoms began at age 19 yr 5-6 day episodes of recurrent, severe vomiting
More informationPalliative Medicine in Critical Care Not Just Hospice. Robin. Truth or Myth 6/11/2015. Francine Arneson, MD Palliative Medicine
Palliative Medicine in Critical Care Not Just Hospice Francine Arneson, MD Palliative Medicine Robin 45 year old female married, husband in Afghanistan. 4 children ages 17-24. Mother has been providing
More informationIf we are going to treat this, of course it's like most things, we want to treat the underlying cause as well as the effect.
Systemic Management of Nausea: Antiemetics Bruce Flint O.D. Antiemetics: This is for controlling nausea and vomiting. These are multiple conditions that's causing this. It's kind of common. I'm sure all
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 6/15/18 Pharmacy- Formulary 1 x Next Review: 6/19 Pharmacy- Formulary 2 x Date of Origin: 4/99 Antiemetic Agents: Zofran /ODT (ondansetron/ondansetron
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationSymptom Management for Patients Near End of Life
Symptom Management for Patients Near the End of Life Ritchell R. Dignam, MD Medical Director Vitas Healthcare 856-778-0222 Objectives Review the etiology and pathophysiology of common non-pain symptoms
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationPsychology of Pain DR. ARNEL BANAGA SALGADO,
Psychology of Pain DR. ARNEL BANAGA SALGADO, Doctor of Psychology (USA) FPM (Ph.D.) Psychology (India) Doctor of Education (Phl) Master of Arts in Nursing (Phl) Master of Arts in Teaching Psychology (PNU)
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationControlling nausea and vomiting: anti-emetic therapy advice
Controlling nausea and vomiting: anti-emetic therapy advice Chemotherapy A guide for patients and carers Contents Treatments that may cause nausea and vomiting... 2 Physical reasons that may cause nausea
More informationMedications used for symptom control in palliative care
Learning Objectives used for symptom control in palliative care Luis Viana, R. Ph., M.Ed., CGP 1. For common symptoms experienced by the person managed with palliative care: Recognize the symptom to be
More informationPropulsion and mixing of food in the alimentary tract Chapter 63
Propulsion and mixing of food in the alimentary tract Chapter 63 Types of GI movements: Propulsive movement-peristalsis Propulsion: controlled movement of ingested foods, liquids, GI secretions, and sloughed
More informationConstipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment
CONSTIPATION Constipation An Overview Definition Physiology of GI tract Etiology Assessment Treatment Definition Constipation = the infrequent passage of hard feces Definition of Infrequent The meaning
More informationAcute GI effects of radiotherapy
Acute GI effects of radiotherapy Dr Alex Stewart Hon Senior Lecturer, University of Surrey Clinical Director, St Luke s Cancer Centre, University of Surrey, Guildford Learning Objectives Acute Radiotherapy
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationUsing syringe pumps in palliative care
Using syringe pumps in palliative care Facilitator: Barbara Stone RN Ground rules Medication matching game Learning outcomes To identify the indications for using a syringe pump To discuss the general
More informationDOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the
DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationClatterbridge Centre for Oncology
Clatterbridge Centre for Oncology CONTENTS 1. Why and when to use a syringe driver 2. Siting the syringe driver 3. Mixing and measuring 4. Setting up the syringe driver 5. Drug information 6. Common problems
More informationSymptom Management Pocket Guides: DELIRIUM
Symptom Management Pocket Guides: DELIRIUM August 2010 DELIRIUM Page Considerations. 1 Assessment 2 Diagnosis. 3 Non-Pharmacological treatment 3 Pharmacological treatment. 5 Mild Delirium... 6 Moderate
More informationDrug Class Review on Newer Antiemetics
Drug Class Review on Newer Antiemetics Final Report January 2006 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationSupportive Care for Patients with Cancer
3:15pm - 4:15pm: Breakout 4 - Oncology Option A: Supportive Care for Patients with Cancer ACPE UAN 0107-0000-10-021-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives for Pharmacists:
More informationPage 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories
Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS risk factors from the categories listed below more than one drug prophylaxis (see Appendix A for antiemetic choices) Patient scheduled for surgery Assess patient
More informationCopy right protected Page 1
DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationVOMITING. Tan Lay Zye
VOMITING Tan Lay Zye Vomiting is a common symptom. It is a complex reflex behavioural response involving forceful expulsion of the stomach contents through oral cavity. Contents Emetic reflex Causes of
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationAnticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO
Anticipatory Medications for End of Life Patients oses must be proportional to the current analgesic medication Please refer ALL patients on Methadone or Ketamine to palliative care team for advice. Patients
More information7/13/16. Pharmaceuticals that alter GI motility. Financial disclosures. Common pharmaceuticals that alter GI Motility (an incomplete list) None
Pharmaceuticals that alter GI motility Megan Taylor, ND AANP 2016 Motility Bootcamp Financial disclosures None Common pharmaceuticals that alter GI Motility (an incomplete list) Analgesics Opioids NSAIDs
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More information